Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

Share Price is delayed by 15 minutes
Get Live Data
700.00    0.00 (0.00%)
Bid:
694.00
Ask:
702.00
Spread: 8.00 (1.153%)
Market Cap: £346.93m
ELIX Live PriceLast checked at - London Stock Exchange

Intraday Elixirr International Share Chart

PDMR Dealing

27 Jul 2020 07:00

RNS Number : 0882U
Elixirr International PLC
27 July 2020
 

ELIXIRR INTERNATIONAL PLC

("Elixirr", the "Company" or the "Group")

PDMR Dealing

 

Elixirr, an established, global award-winning challenger consultancy, announces that it was notified on 24 July 2020, that on that same day, Nicholas Willott, Finance Director and PDMR of the Company, acquired 7,421 ordinary shares of 0.005p each in the Company ("Ordinary Shares") at a price of 202 pence per Ordinary Share.

Following the purchase, Nicholas Willott's beneficial holding is 342,221 Ordinary Shares, representing 0.76% of the issued share capital of the Company.

 

For further Information please contact:

 

Elixirr International plc

Stephen Newton, CEO

Graham Busby, CFO

 

 

 

Public and Investor Relations contacts:

Caroline Pitt

Jazz Berry

 

finnCap Ltd (Nominated Adviser & Sole Broker)

Christopher Raggett, Simon Hicks, Kate Bannatyne (Corporate Finance)

Andrew Burdis, Sunila De Silva (ECM)

 

 

investor-relations@elixirr.com

 

 

+44 (0)20 7220 0500

About Elixirr International plc

Elixirr is an established global award-winning management consultancy, challenging the larger consultancies by delivering innovative and bespoke solutions to a repeat, globally-recognised client base.

Elixirr was founded in 2009, by Stephen Newton, Graham Busby, Ian Ferguson, Andy Curtis and Mark Goodyear, experienced business advisors who identified a market opportunity to provide bespoke, personal services as a 'challenger' to the traditional consultancy businesses in the market. Elixirr guides its clients to overcome challenges such as: future-proofing against technological disruption; development and roll-out of new propositions, products and services; incubating new businesses; navigating a more complex and multinational regulatory environment; and project management and implementation of major change programmes.

The information communicated in this announcement includes inside information for the purposes of Article 7 Regulation 596/2014.

 

 

The notification below, made in accordance with requirements of the EU Market Abuse Regulation, provides further details.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Nicholas Willott

2.

Reason for the Notification

a)

Position/status

Finance Director and PDMR

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Elixirr International plc

b)

LEI

213800MKY7OHMVAKW681

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 0.005p each ("Ordinary Shares")

Identification code

GB00BLPHTX84

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

202p

7,421

d)

Aggregated information:

· Aggregated volume

· Price

 

7,421 Ordinary Shares at 202p

e)

Date of the transaction

24 July 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHRFMJTMTTTBJM
Date   Source Headline
25th Oct 202412:01 pmRNSDirector/PDMR Shareholding
25th Oct 20247:00 amRNSResult of Secondary Placing
24th Oct 20244:35 pmRNSProposed Secondary Placing
21st Oct 20247:00 amRNSAcquisition of Hypothesis Group, LLC
14th Oct 20247:00 amRNSRevolving Credit Facility
1st Oct 20247:00 amRNSInvestor Presentation
23rd Sep 20247:00 amRNSInterim Results
31st Jul 20245:00 pmRNSDirector/PDMR Shareholding
25th Jul 20247:00 amRNSPDMR/PCA Dealings
12th Jul 20244:15 pmRNSDirector/PDMR Shareholding
9th Jul 202411:45 amRNSPurchase of Shares by Employee Benefit Trust
3rd Jul 202410:30 amRNSDirector Dealing
25th Jun 20249:55 amRNSResult of AGM
31st May 20247:00 amRNSPosting of Annual Report and Accounts
21st May 20246:20 pmRNSDirector Declaration
24th Apr 20247:00 amRNSGrant of Share Options
22nd Apr 20247:00 amRNSFinal Results
8th Apr 20247:00 amRNSNotice of FY 23 Results and Investor Presentation
26th Jan 20247:00 amRNSDirector Dealing
8th Jan 20247:00 amRNSTrading Update and Change to Dividend Policy
11th Dec 20237:00 amRNSAcquisition of Insigniam LLC and Insigniam SAS
18th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSAcquisition of Responsum, Inc.
13th Jun 202310:45 amRNSResult of AGM
24th May 20231:31 pmRNSHolding(s) in Company
19th May 20237:00 amRNSPosting of Annual Report and Accounts
10th May 20233:00 pmRNSDirector/PCA Dealings
26th Apr 20237:00 amRNSGrant of Share Options
12th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
4th Apr 20233:00 pmRNSDirector Dealing
3rd Apr 20239:15 amRNSDirector Dealing
3rd Apr 20237:00 amRNSFinal Results
28th Mar 20237:00 amRNSInvestor Presentation
27th Feb 20239:05 amRNSSecond Price Monitoring Extn
27th Feb 20239:00 amRNSPrice Monitoring Extension
27th Feb 20237:00 amRNSTrading Update
24th Feb 20232:05 pmRNSSecond Price Monitoring Extn
24th Feb 20232:00 pmRNSPrice Monitoring Extension
24th Feb 202311:05 amRNSSecond Price Monitoring Extn
24th Feb 202311:00 amRNSPrice Monitoring Extension
29th Nov 20221:15 pmRNSInvestor Presentation
11th Nov 20227:00 amRNSDirector Dealing
20th Oct 20227:00 amRNSPCA Dealing
6th Oct 20227:00 amRNSPurchase of Shares by Employee Benefit Trust
20th Sep 20227:00 amRNSInterim Results
12th Sep 20227:00 amRNSNotice of Interim Results
29th Jul 20224:41 pmRNSSecond Price Monitoring Extn
29th Jul 20224:35 pmRNSPrice Monitoring Extension
11th Jul 20221:45 pmRNSPDMR/PCA Dealing
7th Jul 202211:15 amRNSPCA Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.